Mafenide

Mafenide

Clinical data
Trade names	Sulfamylon, Mafylon
AHFS/Drugs.com	Monograph
Routes of administration	Topical
ATC code	D06BA03 ( WHO )
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-(Aminomethyl)benzenesulfonamide
CAS Number	138-39-6  N
PubChem CID	3998
DrugBank	DB06795  Y
ChemSpider	3858  Y
UNII	58447S8P4L
KEGG	D02351  Y
ChEMBL	ChEMBL419  Y
CompTox Dashboard (EPA)	DTXSID6047860
ECHA InfoCard	100.004.843
Chemical and physical data
Formula	C7H10N2O2S
Molar mass	186.23 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=S(=O)(c1ccc(cc1)CN)N
InChI InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11) Y Key:TYMRLRRVMHJFTF-UHFFFAOYSA-N Y
NY  (what is this?)    (verify)

Mafenide (INN; usually as mafenide acetate, trade name Sulfamylon) is a sulfonamide-type medication used as an antibiotic. It was approved by the FDA in 1948.^{[ citation needed ]}

Uses

Mafenide is used to treat severe burns. ^{[1] [2]} It is used topically as an adjunctive therapy for second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns. ^[3]

Mechanism of action

Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns. ^{[ citation needed ]}

Adverse reactions

Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis. ^[4]

Drug interactions

There are no significant interactions.^{[ citation needed ]}

Contraindications

Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.

Dosage

For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.^{[ citation needed ]}

References

1. Siuda JF, Cihonski CD (November 1972). "New compounds: carbamate derivatives of mafenide (homosulfanilamide)". Journal of Pharmaceutical Sciences. 61 (11): 1856–1857. doi:10.1002/jps.2600611143. PMID   4652670.
2. Haynes BW (June 1971). "Mafenide acetate in burn treatment". The New England Journal of Medicine. 284 (23): 1324. doi:10.1056/NEJM197106102842310. PMID   5576444.
3. Haik J, Ashkenazy O, Sinai S, Tessone A, Barda Y, Winkler E, et al. (November 2005). "Burn care standards in Israel: lack of consensus". Burns. 31 (7): 845–849. doi:10.1016/j.burns.2005.04.012. PMID   15967581.
4. "Sulfamylon (Mafenide Acetate)". RxList. Retrieved 22 December 2022.

External links

• Mafenide information on RxList